Abstract
Cognition and gait appear to be closely related. The chronological interplay between cognitive decline and gait dysfunction is not fully understood. The aim of the present prospective study is investigating whether the dysfunction of specific gait parameters, during specific task and medication conditions, may predict subsequent cognitive impairment in Parkinson’s disease (PD). We evaluated cognition and gait in 39 Parkinsonian patients at an initial assessment and after 3 years. Cognitive performance was evaluated with a neuropsychological battery designed to assess memory, executive/attention, and visuospatial domains. Gait was investigated using a gait analysis system during both the off and on states in the following conditions: (1) normal gait; (2) motor dual task; and (3) cognitive dual task. We used regression models to determine whether gait predicts subsequent cognitive dysfunction. Overall, the cognitive test scores were stable over time with the exception of the executive/attention scores, whereas all gait parameters declined. The step length during the cognitive dual task during the on state at the initial evaluation was the only significant predictor of executive/attention domain dysfunction at follow up. The results were confirmed when executive/attention dysfunction at the initial assessment evaluation was included in the regression model as a covariate. Our longitudinal study offers additional insight into the progression of gait dysfunction, and its chronological relationship with cognitive dysfunction in PD patients. In particular, the present study indicates that step length during a cognitive task when on medication is an independent predictor of future executive/attention decline.
Similar content being viewed by others
References
Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D (2011) Cognitive impairment in nondemented Parkinson’s disease. Mov Disord 26:2483–2495
Muslimović D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65:1239–1245
Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jiménez-Urbieta H, Rodriguez-Oroz MC (2016) Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov Disord 31:861–881
Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 48:938–942
Levy BR, Slade MD, Kunkel SR, Kasl SV (2002) Longevity increased by positive self-perceptions of aging. J Pers Soc Psychol 83:261
Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D (2014) What can biomarkers tell us about cognition in Parkinson’s disease? Mov Disord 29:622–633
Amboni M, Barone P, Hausdorff JM (2013) Cognitive contributions to gait and falls: evidence and implications. Mov Disord 28:1520–1533
Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J et al (2003) Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 18:884–889
Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D (2006) Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 21:1123–1130
Uc E, Rizzo M, Anderson S, Qian S, Rodnitzky R, Dawson J (2005) Visual dysfunction in Parkinson disease without dementia. Neurology 65:1907–1913
Domellöf ME, Elgh E, Forsgren L (2011) The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson’s disease. Mov Disord 26:2183–2189
Amboni M, Barone P, Iuppariello L, Lista I, Tranfaglia R, Fasano A et al (2012) Gait patterns in Parkinsonian patients with or without mild cognitive impairment. Mov Disord 27:1536–1543
Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR (2016) Unmasking levodopa resistance in Parkinson’s disease. Mov Disord 31(11):1602–1609
Verghese J, Wang C, Lipton RB, Holtzer R, Xue X (2007) Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry 78:929–935
Mielke MM, Roberts RO, Savica R, Cha R, Drubach DI, Christianson T et al (2013) Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 68:929–937
Morris R, Lord S, Bunce J, Burn D, Rochester L (2016) Gait and cognition: mapping the global and discrete relationships in ageing and neurodegenerative disease. Neurosci Biobehav Rev 64:326–345
Rochester L, Galna B, Lord S, Yarnall AJ, Morris R, Duncan G et al (2017) Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease. Neurology 88(16):1501–1511
Morris R, Lord S, Lawson RA, Coleman S, Galna B, Duncan GW et al (2017) Gait rather than cognition predicts decline in specific cognitive domains in early Parkinson’s disease. J Gerontol A Biol Sci Med Sci 72(12):1656–1662
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707
Caltagirone C, Gainotti G, Masullo C, Miceli G (1979) Validity of some neuropsychological tests in the assessment of mental deterioration. Acta Psychiatr Scand 60:50–56
Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626
Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E (1998) A normative study on visual reaction times and two Stroop colour–word tests. Ital J Neurol Sci 19:161–170
Manos PJ, Wu R (1994) The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. Int J Psychiatry Med 24:229–244
Spinnler H, Tognoni G (1987) Italian Group on the Neuropsychological Study of Ageing: Italian standardization and classification of neuropsychological tests. Ital J Neurol Sci 6:1–120
Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J et al (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75:1062–1069
Field A (2013) Discovering statistics using IBM SPSS statistics. Sage, London
Reinoso G, Allen JC Jr, Au WL, Seah SH, Tay KY, Tan LC (2015) Clinical evolution of Parkinson’s disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22:457–463
Galna B, Lord S, Burn DJ, Rochester L (2015) Progression of gait dysfunction in incident Parkinson’s disease: impact of medication and phenotype. Mov Disord 30:359–367
Brown R, Marsden C (1990) Cognitive function in Parkinson’s disease: from description to theory. Trends Neurosci 13:21–29
Azuma T, Cruz RF, Bayles KA, Tomoeda CK, Montgomery EB (2003) A longitudinal study of neuropsychological change in individuals with Parkinson’s disease. Int J Geriatr Psychiatry 18:1115–1120
Muslimović D, Post B, Speelman JD, De Haan RJ, Schmand B (2009) Cognitive decline in Parkinson’s disease: a prospective longitudinal study. J Int Neuropsychol Soc 15:426–437
Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE et al (2015) Longitudinal study of normal cognition in Parkinson disease. Neurology 85:1276–1282
Pedersen KF, Larsen JP, Tysnes O-B, Alves G (2013) Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 70:580–586
Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K et al (2015) Mild cognitive impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226
Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH et al (2017) Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J Neurol Neurosurg Psychiatry 88(8):648–652
Marras C, Armstrong MJ, Meaney CA, Fox S, Rothberg B, Reginold W et al (2013) Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord 28:626–633
Rochester L, Baker K, Nieuwboer A, Burn D (2011) Targeting dopa-sensitive and dopa-resistant gait dysfunction in Parkinson’s disease: Selective responses to internal and external cues. Mov Disord 26:430–435
Curtze C, Nutt JG, Carlson-Kuhta P, Mancini M, Horak FB (2015) Levodopa is a double-edged sword for balance and gait in people with Parkinson’s disease. Mov Disord 30:1361–1370
Rochester L, Yarnall AJ, Baker MR, David RV, Lord S, Galna B et al (2012) Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain 135:2779–2788
Bohnen NI, Frey KA, Studenski S, Kotagal V, Koeppe RA, Scott PJ et al (2013) Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 81:1611–1616
Blin O, Ferrandez A, Pailhous J, Serratrice G. Sci (1991) Dopa-sensitive and dopa-resistant gait parameters in Parkinson’s disease. J Neurol 103:51–54
Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM (2003) Gait dynamics in Parkinson’s disease: relationship to Parkinsonian features, falls and response to levodopa. J Neurol Sci 212:47–53
Lord S, Howe T, Greenland J, Simpson L, Rochester L (2011) Gait variability in older adults: a structured review of testing protocol and clinimetric properties. Gait Posture 34:443–450
Lord S, Galna B, Rochester L (2013) Moving forward on gait measurement: toward a more refined approach. Mov Disord 28(11):1534–1543
Lord S, Galna B, Coleman S, Yarnall A, Burn D, Rochester L (2014) Cognition and gait show a selective pattern of association dominated by phenotype in incident Parkinson’s disease. Front Aging Neurosci 6:249
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
MA, LI, AI, AF, RP, RR, MP, IL, PV, CV, MC, and GS have no financial disclosures to report; PB reports personal fees from Acorda, Union Chimique Belge, Zambon, Grants from Abbvie, Biotie, and Zambon. On behalf of all authors, the corresponding author states that there is no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Amboni, M., Iuppariello, L., Iavarone, A. et al. Step length predicts executive dysfunction in Parkinson’s disease: a 3-year prospective study. J Neurol 265, 2211–2220 (2018). https://doi.org/10.1007/s00415-018-8973-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-8973-x